Drug Profile
Hepatitis B vaccine recombinant - Biogen Idec
Alternative Names: HBY; HebsulinLatest Information Update: 02 Aug 2023
Price :
$50
*
At a glance
- Originator Biogen Idec
- Class DNA vaccines; Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis B
Most Recent Events
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 17 Nov 2003 IDEC Pharmaceuticals has merged with Biogen to form Biogen Idec
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation